A meta-analysis of patients with chronic hepatitis C treated with interferon-alpha to determine the risk of autoimmune thyroiditis;Un meta-análisis de pacientes con hepatitis C crónica tratados con interferón-alfa para determinar el riesgo de tiroiditis autoinmune

Acta Gastroenterologica Latinoamericana

Volumn 41, Issue 2, 2011, Pages 104-110

  de Oliveira Andrade, Luis Jesuino ^a,b   Junior, Argemiro D'Oliveira ^b   Costa Silva, Carolina Alves ^b   Nunes, Paulo ^b   França, Larissa Santos ^c   Malta, Ana Micheline Andrade ^c   Paraná, Raymundo ^b  

^a DEPARTAMENTO DE CIÊNCIAS BIOLÓGICAS   (Brazil)

^b FEDERAL UNIVERSITY OF BAHIA   (Brazil)

^c Faculdade de Tecnologia e Ciencias   (Brazil)

Author keywords

Autoimmunity; Hepatitis B virus; Hepatitis C virus; Interferon alpha; Meta analysis; Thyroid

Indexed keywords

ALPHA INTERFERON;

AUTOIMMUNE THYROIDITIS; DATA BASE; DATA EXTRACTION; EMBASE; HEPATITIS B; HEPATITIS C; HUMAN; MEDLINE; META ANALYSIS; OUTCOME ASSESSMENT; REVIEW; RISK FACTOR; SYSTEMATIC REVIEW;

ADULT; AGED; ANTIVIRAL AGENTS; CASE-CONTROL STUDIES; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; RISK FACTORS; THYROIDITIS, AUTOIMMUNE;

EID: 79960174155     PISSN: 03009033     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (53)

1. Andrade LJ, D'Oliveira A, Melo RC, De Souza EC, Silva CA, Paraná R. Association between hepatitis C and hepatocellular carcinoma. J Global Infect Dis 2009;1:33-37.
2. WHO. Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium. J Viral Hepat 1999;6:35-47.
3. Global Burden of Hepatitis C Working Group. Global burden of disease (GBD) for hepatitis C. J Clin Pharmacol 2004;44:20-29.
4. Tomer Y, Villanueva R. Hepatitis C and thyroid autoimmunity: is there a link? Am J Med 2004;117:60-61.
5. Selmi C, Lleo A, Zuin M, Podda M, Rossaro L, Gershwin ME. Interferon alpha and its contribution to autoimmunity. Curr Opin Investig Drugs 2006;7:451-456.
6. Strader DB, Wright T, Thomas DL, Seeff LB. American Association for the Study of Liver Diseases practice guideline: diagnosis, management, and treatment of hepatitis C. Hepatology 2004;39:1147-1171.
7. Prummel MF, Laurberg P. Interferon-alpha and autoimmune thyroid disease. Thyroid 2003;13:547-551.
8. Der Simonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-188.
9. Lisker-Melman M, Di Bisceglie AM, Usala SJ, Weintraub B, Murray LM, Hoofnagle JH. Development of thyroid disease during therapy of chronic viral hepatitis with interferon alpha. Gastroenterology 1992;102:2155-2160.
10. Baudin E, Marcellin P, Pouteau M, Colas-Linhart N, Le Floch JP, Lemmonier C, Benhamou JP, Bok B. Reversibility of thyroid dysfunction induced by recombinant alpha interferon in chronic hepatitis C. Clin Endocrinol (Oxf) 1993;39:657-661.
11. Tran A, Quaranta JF, Benzaken S, Thiers V, Chau HT, Hastier P, Regnier D, Dreyfus G, Pradier C, Sadoul JL. High prevalence of thyroid autoantibodies in a prospective series of patients with chronic hepatitis C before interferon therapy. Hepatology 1993;18:253-257.
12. Nagayama Y, Ohta K, Tsuruta M, Takeshita A, Kimura H, Hamasaki K, Ashizawa K, Nakata K, Yokoyama N, Nagataki S. Exacerbation of thyroid autoimmunity by interferon: a treatment in patients with chronic viral hepatitis: our studies and review of the literature. Endocr J 1994;41:565-572.
13. Watanabe U, Hashimoto E, Hisamitsu T, Obata H, Hayashi N. The risk factors for development of thyroid disease during interferon alpha therapy for chronic hepatitis C. Am J Gastroenterol 1994;89:399-403.
14. Chedin P, Chanson P, Duranteau L, Guillausseau PJ, Lubetzki J. Dysthyroidism in patients treated with interferon alpha. Presse Med 1994; 23:1659-1663.
15. Murakami T, Masumoto T, Michitaka K, Horiike N, Hino H, Okada S, Kitaj K, Onji M. Prediction of interferon-alpha- induced thyroid dysfunction in patients with chronic hepatitis C. J Gastroenterol Hepatol 1995;10:528-531.
16. Del Monte P, Bernasconi D, De Conca V, Randazzo M, Meozzi M, Badaracco B, Mesiti S, Marugo M. Endocrine evaluation in patients treated with interferon-alpha for chronic hepatitis C. Horm Res 1995;44:105-109.
17. Imagawa A, Itoh N, Hanafusa T, Oda Y, Waguri M, Miyagawa J, Kono N, Kuwajima M, Matsuzawa Y. Autoimmune endocrine disease induced by recombinant interferon-a therapy for chronic active type C hepatitis. J Clin Endocrinol Metab 1995;80:922-926.
18. Carella C, Amato G, Biondi B, Rotondi M, Morisco F, Tuccillo C, Chiuchiolo N, Signoriello G, Caporaso N, Lombardi G. Longitudinal study of antibodies against thyroid in patients undergoing interferon-alpha therapy for HCV chronic hepatitis. Horm Res 1995;44:110-114.
19. Preziati D, La Rosa L, Covini G, Marcelli R, Rescalli S, Persani L, Del Ninno E, Meroni PL, Colombo M, Beck-Peccoz P. Autoimmunity and thyroid function in patients with chronic active hepatitis treated with recombinant interferon alpha-2a. Eur J Endocrinol 1995; 132:587-593.
20. Okanoue T, Sakamoto S, Itoh Y, Minami M, Yasui K, Sakamoto M, Nishioji K, Katagishi T, Nakagawa Y, Tada H, Sawa Y, Mizuno M, Kagawa K, Kashima K. Side effects of high-dose interferon therapy for chronic hepatitis C. J Hepatol 1996;25:283-291.
21. Roti E, Minelli R, Giuberti T, Marchelli S, Schianchi C, Gardini E, Salvi M, Fiaccadori F, Ugolotti G, Neri TM, Braverman LE. Multiple changes in thyroid function in patients with chronic active HCV hepatitis treated with recombinant interferon-alpha. Am J Med 1996;101:482-487.
22. Marazuela M, García-Buey L, González-Fernández B, García-Monzón C, Arranz A, Borque MJ, Moreno-Otero R. Thyroid autoimmune disorders in patients with chronic hepatitis C before and during interferon-alpha therapy. Clin Endocrinol (Oxf) 1996;44:635-642.
23. Custro N, Montalto G, Scafidi V, Soresi M, Gallo S, Tripi S, Notarbartolo A. Prospective study on thyroid autoimmunity and dysfunction related to chronic hepatitis C and interferon therapy. J Endocrinol Invest 1997; 20:374-380.
24. Kiehne K, Kloehn S, Hinrichsen H, Gallwitz B, Mönig H. Thyroid autoantibodies and thyroid dysfunction during treatment with interferon-alpha for chronic hepatitis C. Endocrine 1997;6:231-234.
25. Floreani A, Chiaramonte M, Greggio NA, Fabris P, De Lazzari F, Naccarato R, Betterle C. Organ-specific autoimmunity and genetic predisposition in interferontreated HCVrelated chronic hepatitis patients. Ital J Gastroenterol Hepatol 1998;30:71-76.
26. Nduwayo L, Bacq Y, Valat C, Goudeau A, Lecomte P. Thyroid function and autoimmunity in 215 patients seropositive for the hepatitis C virus. Ann Endocrinol 1998;59:9-13.
27. Deutsch M, Dourakis S, Manesis EK, Gioustozi A, Hess G, Horsch A, Hadziyannis S. Thyroid abnormalities in chronic viral hepatitis and their relationship to Interferon alpha therapy. Hepatology 1997;26:206-210.
28. Fernandez-Soto L, Gonzalez A, Escobar-Jimenez F, Vazquez R, Ocete E, Olea N, Salmeron J. Increased risk of autoimmune thyroid disease in hepatitis C vs hepatitis B before, during, and after discontinuing interferon therapy. Arch Intern Med 1998;158:1445-1448.
29. Murakami M, Kakizaki S, Takayama H, Takagi H, Mori M. Autoimmune thyroid disease induced by interferon therapy. Nippon Rinsho 1999; 57:1779-1783.
30. Huang MJ, Tsai SL, Huang BY, Sheen IS, Yeh CT, Liaw YF. Prevalence and significance of thyroid autoantibodies in patients with chronic hepatitis C virus infection: a prospective controlled study. Clin Endocrinol (Oxf) 1999;50:503-509.
31. Cacoub P, Renou C, Rosenthal E, Cohen P, Loury I, Loustaud- Ratti V, Yamamoto AM, Camproux AC, Hausfater P, Musset L, Veyssier P, Raguin G, Piette JC. Extrahepatic manifestations associated with hepatitis C virus infection. A prospective multicenter study of 321 patients. The GERMIVIC Groupe d'Etude et de Recherche en Médecine Interne et Maladies Infectieuses sur le Virus de l'Hépatite C. Medicine (Baltimore) 2000;79:47-56.
32. Kryczka W, Brojer E, Kowalska A, Zarebska-Michaluk D. Thyroid gland dysfunctions during antiviral therapy of chronic hepatitis C. Med Sci Monit 2001;7(suppl 1):221-225.
33. Rocco A, Gargano S, Provenzano A, Nardone M, De Sanctis GM, Altavilla N, Chircu LV, Grimaldi F. Incidence of autoimmune thyroiditis in interferon-alpha treated and untreated patients with chronic hepatitis C virus infection. Neuroendocrinol Lett 2001;22:39-44.
34. Carella C, Mazziotti G, Morisco F, Manganella G, Rotondi M, Tuccillo C, Sorvillo F, Caporaso N, Amato G. Longterm outcome of interferon-alpha-induced thyroid autoimmunity and prognostic influence of thyroid autoantibody pattern at the end of treatment. J Clin Endocrinol Metab 2001;86:1925-1929.
35. Morisco F, Mazziotti G, Rotondi M, Tuccillo C, Iasevoli P, Del Buono A, Sorvillo F, Amato G, Marmo R, Caporaso N, Carella C. Interferon-related thyroid autoimmunity and long-term clinical outcome of chronic hepatitis C. Dig Liver Dis 2001;33:247-253.
36. Mazziotti G, Sorvillo F, Stornaiuolo G, Rotondi M, Morisco F, Ruberto M, Cioffi M, Amato G, Caporaso N, Gaeta GB, Carella C. Temporal relationship between the appearance of thyroid autoantibodies and development of destructive thyroiditis in patients undergoing treatment with two different type-1 interferons for HCV-related chronic hepatitis: a prospective study. J Endocrinol Invest 2002;25: 624-630.
37. Carella C, Mazziotti G, Morisco F, Rotondi M, Cioffi M, Tuccillo C, Sorvillo F, Caporaso N, Amato G. The addition of ribavirin to interferon-alpha therapy in patients with hepatitis C virus-related chronic hepatitis does not modify the thyroid autoantibody pattern but increases the risk of developing hypothyroidism. Eur J Endocrinol 2002;146:743-749.
38. Bini EJ, Mehandru S. Incidence of thyroid dysfunction during interferon alfa-2b and ribavirin therapy in men with chronic hepatitis C. Arch Intern Med 2004;164:2371-2376.
39. Antonelli A, Ferri C, Pampana A, Fallahi P, Nesti C, Pasquini M, Marchi S, Ferrannini E. Thyroid disorders in chronic hepatitis C. Am J Med 2004;117:10-13.
40. Moncoucy X, Leymarie F, Delemer B, Lévy S, Bernard- Chabert B, Bouché O, Jolly D, Diebold MD, Cadiot G, Thiéfin G. Risk factors and long-term course of thyroid dysfunction during anti-viral treatments in 221 patients with chronic hepatitis C. Gastroenterol Clin Biol 2005;29: 339-345.
41. Kabbaj N, Guedira MM, El Atmani H, El Alaoui M, Mohammadi M, Benabed K, Lachkar H, Benaïssa A. Thyroid disorders during interferon alpha therapy in 625 patients with chronic hepatitis C: a prospective cohort study. Ann Endocrinol (Paris) 2006;67:343-347.
42. Huang JF, Chuang WL, Dai CY, Chen SC, Lin ZY, Lee LP, Lee PL, Wang LY, Hsieh MY, Chang WY, Yu ML. The role of thyroid autoantibodies in the development of thyroid dysfunction in Taiwanese chronic hepatitis C patients with interferon-alpha and ribavirin combination therapy. J Viral Hepat 2006;13:396-401.
43. Gehring S, Kullmer U, Koeppelmann S, Gerner P, Wintermeyer P, Wirth S. Prevalence of autoantibodies and the risk of autoimmune thyroid disease in children with chronic hepatitis C virus infection treated with interferon-alpha. World J Gastroenterol 2006;12:5787-5792.
44. Tarantino G, Gagliardi G, Conca P. Do thyroid abnormalities detected in patients treated for HCV-related chronic hepatitis persist? Int J Immunopathol Pharmacol 2008;21: 467-469.
45. Manns MP, Wedemeyer H, Cornberg C. Treating viral hepatitis C: efficacy, side effects and complications. Gut 2006;55:1350-1359.
46. Loviselli A, Oppo A, Velluzzi F, Atzeni F, Mastinu GL, Farci P, Orgiana G, Balestrieri A, Cocco PL, Mariotti S. Independent expression of serological markers of thyroid autoimmunity and hepatitis C virus infection in the general population: results of a community-based study in northwestern Sardinia. J Endocrinol Invest 1999;22:660-665.
47. Metcalfe RA, Ball G, Kudesia G, Weetman AP. Failure to find an association between hepatitis C virus and thyroid autoimmunity. Thyroid 1997;7:421-424.
48. Boadas J, Rodriguez-Espinosa J, Enriquez J, Miralles F, Martinez-Cerezo FJ, González P, Madoz P, Vilardell F. Prevalence of thyroid autoantibodies is not increased in blood donors with hepatitis C virus infection. J Hepatol 1995;22:611-615.
49. Ganne-Carrie N, Medini A, Coderc E, Seror O, Christidis C, Grimbert S, Trinchet JC, Beaugrand M. Latent autoimmune thyroiditis in untreated patients withHCVchronic hepatitis: a case control study. J Autoimmun 2000; 14:189-193.
50. Tomer Y, Davies TF. Infection, thyroid disease and autoimmunity. Endocr Rev 1993;14:107-120.
51. Szyper-Kravitz M, Marai I, Shoenfeld Y. Coexistence of thyroid autoimmunity with other autoimmune diseases: friend or foe? Additional aspects on the mosaic of autoimmunity. Autoimmunity 2005;38:247-255.
52. Wang C, Crapo LM. The epidemiology of thyroid disease and implications for screening. Endocrinol Metab Clin North Am 1997;26:189-218.
53. Hsieh MC, Yu ML, Chuang WL, Shin SJ, Dai CY, Chen SC, Lin ZY, Hsieh MY, Liu JF, Wang LY, Chang WY. Virologic factors related to interferon-a-induced thyroid dysfunction in patients with chronic hepatitis C. Eur J Endocrinol 2000;142:431-437.